The management of glaucoma and macular degeneration

References

• Lusthaus J, Goldberg I. Current management of glaucoma. Med J Aust. 2019;210:180–187.
   PubMed Web of Science ®Google Scholar
• Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121:2081–2090.
   PubMed Web of Science ®Google Scholar
• Guglielmi P, Carradori S, Campestre C, et al., Novel therapies for glaucoma: a patent review (2013-2019). Expert Opin Ther Pat. 2019 Aug 11;29(10):769–780. Article in this special issue. DOI:10.1080/13543776.2019.1653279.
   PubMed Web of Science ®Google Scholar
• Mietzner R, Breunig M. Causative glaucoma treatment: promising targets and delivery systems. Drug Discov Today. 2019;24:1606–1613.
   PubMed Web of Science ®Google Scholar
• Garhöfer G, Schmetterer L. Nitric oxide: a drug target for glaucoma revisited. Drug Discov Today. 2019;24:1614–1620.
   PubMed Web of Science ®Google Scholar
• Carta F, Supuran CT, Scozzafava A. Novel therapies for glaucoma: a patent review 2007-2011. Expert Opin Ther Pat. 2012;22:79–88.
   PubMed Web of Science ®Google Scholar
• Masini E, Carta F, Scozzafava A, et al. Antiglaucoma carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23:705–716.
   PubMed Web of Science ®Google Scholar
• Schehlein EM, Robin AL. Rho-associated kinase inhibitors: evolving strategies in glaucoma treatment. Drugs. 2019;79:1031–1036.
   PubMed Web of Science ®Google Scholar
• Ferris FL 3rd, Wilkinson CP, Bird A, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844–851.
   PubMed Web of Science ®Google Scholar
• Horani M, Mahmood S, Aslam TM. Macular atrophy of the retinal pigment epithelium in patients with neovascular age-related macular degeneration: what is the link? Part I: a review of disease characterization and morphological associations. Ophthalmol Ther. 2019;8:235–249.
   PubMed Web of Science ®Google Scholar
• Campbell M, Doyle SL. Current perspectives on established and novel therapies for pathological neovascularization in retinal disease. Biochem Pharmacol. 2019;164:321–325.
   PubMed Web of Science ®Google Scholar
• Velez-Montoya R, Oliver SC, Olson JL, et al. Current knowledge and trends in age-related macular degeneration: genetics, epidemiology, and prevention. Retina. 2014;34:423–441.
   PubMed Web of Science ®Google Scholar
• Mehta S. Age-related macular degeneration. Prim Care. 2015;42:377–391.
   PubMed Web of Science ®Google Scholar
• Léveillard T, Philp NJ, Sennlaub F. Is retinal metabolic dysfunction at the center of the pathogenesis of age-related macular degeneration? Int J Mol Sci. 2019;20:E762.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Ceruso M, Bua S, et al. Discovery of β-adrenergic receptors blocker-carbonic anhydrase inhibitor hybrids for multitargeted antiglaucoma therapy. J Med Chem. 2018;61:5380–5394.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov. 2008;7:168–181.
   PubMed Web of Science ®Google Scholar
• Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? J Enzyme Inhib Med Chem. 2016;31:345–360.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin Ther Pat. 2000;10:575–600.
   Web of Science ®Google Scholar
• Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov. 2017;12:61–88.
   PubMed Web of Science ®Google Scholar
• Lusthaus JA, Goldberg I. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation. Expert Opin Drug Saf. 2017;16:1071–1078.
   PubMed Web of Science ®Google Scholar
• Lu LJ, Tsai JC, Liu J. Novel pharmacologic candidates for treatment of primary open-angle glaucoma. Yale J Biol Med. 2017;90:111–118.
   PubMed Web of Science ®Google Scholar
• Perrino E, Uliva C, Lanzi C, et al. New prostaglandin derivative for glaucoma treatment. Bioorg Med Chem Lett. 2009;19:1639–1642.
   PubMed Web of Science ®Google Scholar
• Spadoni G, Bedini A, Furiassi L, et al. Identification of bivalent ligands with melatonin receptor agonist and fatty acid amide hydrolase (FAAH) inhibitory activity that exhibit ocular hypotensive effect in the rabbit. J Med Chem. 2018;61:7902–7916.
   PubMed Web of Science ®Google Scholar
• Fabrizi F, Mincione F, Somma T, et al. A new approach to antiglaucoma drugs: carbonic anhydrase inhibitors with or without NO donating moieties. Mechanism of action and preliminary pharmacology. J Enzyme Inhib Med Chem. 2012;27:138–147.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitor – NO donor hybrids and their pharmacologic applications. In: Bonavida B, Morbidelli L, editors. Therapeutic applications of nitric oxide in cancer and inflammatory-related disorders. New York: Elsevier; 2019:229–242.
   Google Scholar
• Nocentini A, Supuran CT. Adrenergic agonists and antagonists as antiglaucoma agents: a literature and patent review (2013-2019). Expert Opin Ther Pat. 2019;29(10)805–815. Article in this special issue. DOI:10.1080/13543776.2019.1665023
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Expert Opin Ther Pat. 2018;28:709–712.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. Expert Opin Ther Pat. 2018;28:713–721.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Altamimi ASA, Carta F. Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019. Expert Opin Ther Pat. 2019:29(10); 781–792. Article in this special issue. DOI:10.1080/13543776.2019.1679117.
   Google Scholar
• Nocentini A, Supuran CT, Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery. Expert Opin Drug Discov. 2019 Aug 22;14(11):11751–1197. DOI:10.1080/17460441.2019.1651289.
   Web of Science ®Google Scholar
• Berrino E, Supuran CT. Rho-kinase inhibitors in the management of glaucoma. Expert Opin Ther Pat;2019;29(10):817–827. Article in this special issue. DOI:10.1080/13543776.2019.1670812.
   PubMed Web of Science ®Google Scholar
• Angeli A, Supuran CT. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 – 2018). Expert Opin Ther Pat. 2019;29(10):793–803. Article in this special issue. DOI:10.1080/13543776.2019.1661992
   PubMed Web of Science ®Google Scholar
• Bua S, Supuran CT. Diagnostic markers for glaucoma: a patent and literature review (2013-2018). Expert Opin Ther Pat. 2019;29(10)829–839. Article in this special issue. DOI:10.1080/13543776.2019.1667336
   PubMed Web of Science ®Google Scholar
• Supuran CT. Agents for the prevention and treatment of age-related macular degeneration and macular edema: a literature and patent review. Expert Opin Ther Pat. 2019;29(10):761–767. Article in this special issue. DOI:10.1080/13543776.2019.1671353
   Web of Science ®Google Scholar
• Capasso C, Winum JY. Novel method of treating macular degeneration: A patent evaluation (WO2018/107005). Expert Opin Ther Pat. 2019;29(10):749–752. Article in this special issue. DOI:10.1080/13543776.2019.1661991
   PubMed Web of Science ®Google Scholar
• Bonardi A, Supuran CT, Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595. Expert Opin Ther Pat. 2019 Aug 22;29(10)753–759. Article in this special issue. DOI:10.1080/13543776.2019.1658743.
   Web of Science ®Google Scholar